Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2024 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2024 Earnings Call Transcript November 7, 2024Adaptive Biotechnologies Corporation beats earnings expectations.
Adaptive Biotechnologies Corp (ADPT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 29,993,708 | $153,567,785 | 0.55% | |
| 2. | Rubric Capital Management David Rosen | 14,400,000 | $73,728,000 | +3% | 1.2% |
| 3. | ARK Investment Management Catherine D. Wood | 11,601,134 | $59,397,807 | +2% | 0.54% |
| 4. | Millennium Management Israel Englander | 9,400,573 | $48,130,934 | +2% | 0.02% |
| 5. | Soleus Capital Guy Levy | 1,112,749 | $5,697,275 | -36% | 0.44% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 2,500 | Officer | 2,500 | 2019-07-01 | Filing | |
| $20.00 | 1,000 | Officer | 1,000 | 2019-07-01 | Filing | |
| $20.00 | 300 | Officer | 300 | 2019-07-01 | Filing | |
| $20.00 | 400 | Officer | 400 | 2019-07-01 | Filing | |
| $20.00 | 500 | Officer | 500 | 2019-07-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.98 | 248 | Officer | 154,330 | 2024-11-18 | Filing | |
| $4.50 | 26,922 | Officer | 139,365 | 2024-08-22 | Filing | |
| $3.43 | 7,727 | Officer | 123,318 | 2024-03-05 | Filing | |
| $3.44 | 6,609 | Officer | 166,287 | 2024-03-05 | Filing | |
| $3.43 | 6,772 | Officer | 172,896 | 2024-03-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,767,684 | $62,561,652 | 0% | |
| 2. | 11,421,554 | $55,965,614 | 0% | |
| 3. | 6,511,659 | $31,907,129 | 0.3% | |
| 4. | 6,511,659 | $31,907,129 | 0.02% | |
| 5. | 3,422,356 | $16,769,544 | 0.01% |
News See All
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q2 2024 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q2 2024 Earnings Call Transcript August 1, 2024Adaptive Biotechnologies Corporation beats earnings expectations.
Does Adaptive Biotechnologies Corporation (ADPT) Have Strong Growth Potential?
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2024 Earnings Call Transcript
Adaptive Biotechnologies Corporation beats earnings expectations. Reported EPS is $-0.32586, expectations were $-0.35.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2023 Earnings Call Transcript
Adaptive Biotechnologies Corporation beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.32.
Here’s Why Adaptive Biotechnologies Corporation (ADPT) Declined in Q4
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2023 investor letter. A copy of the same can be downloaded here.
16 Best Penny Stocks To Buy For 2024
The stock market’s optimism wave recently saw a break after latest data showed that the US labor market remains resilient despite consistent rate hikes to curb inflation.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript
Operator: Thank you for standing by. At this time, I would like to welcome everyone to today’s Adaptive Biotechnologies 2023 Third Quarter Earnings Call.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q2 2023 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies Second Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode.
Is it Still Worthy to Invest in Adaptive Biotechnologies (ADPT)?
Aristotle Atlantic Partners, an investment management firm, released its second quarter 2023 investor letter, a copy of which can be downloaded here.